Volume 10, Issue 1 (Vol.10 No.1 Apr 2021)                   rbmb.net 2021, 10(1): 13-19 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Badr Roomi A, Nori W, Mokram Hamed R. Lower Serum Irisin Levels Are Associated with Increased Osteoporosis and Oxidative Stress in Postmenopausal. rbmb.net. 2021; 10 (1) :13-19
URL: http://rbmb.net/article-1-595-en.html
PhD, Ministry of Education, Directorate of Education Thi-Qar, Thi-Qar-64001, Iraq & College of Health and Medical Technology, Al-Ayen University, Thi-Qar-64001, Iraq.
Abstract:   (2381 Views)
Background: Irisin as an exercise-induced myokine was proposed to improve bone health. This study investigated the role of serum irisin (s-irisin) in patients with osteoporosis (OP) through correlating to most biological bone markers and oxidative stress.

Methods: A cross-sectional study recruited an eligible 175 postmenopausal women at Al-Hussien Teaching Hospital, Iraq. They were scanned by DEXA and stratified into two groups based on T-score; the first 95 patients as control group (GI) with −1 ≤ T-score and the second 80 patients as cases group (GII) with T-score ≤ −2.5. Demographic criteria were age, bone mineral density (BMD, g/cm2 ) and T-score. Serum irisin, total serum calcium (s-calcium), serum inorganic phosphate (s-phosphate), serum alkaline phosphatase (s-ALP), serum 25 [OH] vitamin D, the serum parathyroid hormone (s-PTH), serum Carboxy terminal collagen crosslinks (CTx), serum procollagen type I C-termidnal peptide (s-PICP), serum malondialdehyde (s-MDA) and serum superoxide dismutase (s-SOD) were collected from blood samples.

Results: Serum irisin were 31.84 ± 2.65 vs. 20.88 ± 2.71 ng/mL for control and trial groups, respectively. Lower levels of BMD, T-score, 25 [OH] vitamin D, and s-irisin along with a higher serum levels of PTH, CTx, PICP, MDA and SOD were observed in patients with osteoporosis. All parameters were statistically meaningful upon correlation (p< 0.0001), except age and s-calcium (p= 0.0088 and p= 0.187, respectively).

Conclusions: The results showed that, a significantly lower serum irisin levels among osteoporosis women, was intimately correlated to most bone turnover markers and it can be considered as encouraging results for clinical application in prediction and treatment of osteoporosis
Full-Text [PDF 174 kb]   (683 Downloads)    
Type of Article: Original Article | Subject: Biochemistry
Received: 2020/11/2 | Accepted: 2020/11/22 | Published: 2021/05/9

1. Leslie WD, Morin SN. New Developments in Fracture Risk Assessment for Current Osteoporosis Reports. Curr osteoporos Rep. 2020;18(3):115-29. [DOI:10.1007/s11914-020-00590-7] [PMID]
2. Fuleihan GE, Chakhtoura M, Cauley JA, Chamoun N. Worldwide fracture prediction. J Clin Densitom. 2017;20(3):397-424. [DOI:10.1016/j.jocd.2017.06.008] [PMID]
3. Duque, G. (Ed.). Osteosarcopenia: Bone, Muscle and Fat Interactions. Springer. 2019. [DOI:10.1007/978-3-030-25890-0]
4. Shepstone L, Lenaghan E, Cooper C, Clarke S, Fong-Soe-Khioe R, Fordham R, et al. Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. Lancet. 2018;391(10122):741-747. [DOI:10.1016/S0140-6736(17)32640-5]
5. Yang S, Leslie WD, Luo Y, Goertzen AL, Ahmed S, Ward LM, et al. Automated DXA-based finite element analysis for hip fracture risk stratification: a cross-sectional study. Osteoporos Int. 2018;29(1):191-200. [DOI:10.1007/s00198-017-4232-8] [PMID]
6. Forgetta V, Keller-Baruch J, Forest M, Durand A, Bhatnagar S, Kemp JP, et al. Development of a polygenic risk score to improve screening for fracture risk: A genetic risk prediction study. PLoS Med. 2020;17(7):e1003152. [DOI:10.1371/journal.pmed.1003152] [PMID] [PMCID]
7. Lee SB, Lee CH, Kim YJ, Kim HM. Biochemical markers of bone turnover in benign paroxysmal positional vertigo. PLoS One. 2017;12(5):e0176011. [DOI:10.1371/journal.pone.0176011] [PMID] [PMCID]
8. Høiberg MP, Rubin KH, Hermann AP, Brixen K, Abrahamsen B. Diagnostic devices for osteoporosis in the general population: a systematic review. Bone. 2016;92:58-69. [DOI:10.1016/j.bone.2016.08.011] [PMID]
9. Grygiel-Gorniak B, Puszczewicz M. A review on irisin, a new protagonist that mediates muscle-adipose-bone-neuron connectivity. Eur Rev Med Pharmacol Sci. 2017;21(20):4687-4693.
10. Al-Badry SH, Khalaf SA, Khalaf, SA Al-Khuzaiy AL, Roomi A. The effects of irisin on the transforming growth factor-beta1 (TGF-β1) level in type-1 diabetic patients in Thi-Qar province. International Journal of Pharmaceutical Research. 2020;12(4). [DOI:10.31838/ijpr/2020.12.04.349]
11. Luo Y, Ma Y, Qiao X, Zeng R, Cheng R, Nie Y, Li S, Shen X, Yang M, Xu CC, Xu L. Irisin ameliorates bone loss in ovariectomized mice. Climacteric. 2020 Apr 21:1-9.
12. Mizil, Oda. (2002). The level of malondialdehyde after activation with (H202 and CuSO4) and inhibition by desferoxamine and molsidomine in the serum of patients with acute myocardial infection. National J of chemistry. 5. 139-148.
13. Abrahin O, Rodrigues RP, Marçal AC, Alves EA, Figueiredo RC, de Sousa EC. Swimming and cycling do not cause positive effects on bone mineral density: a systematic review. Rev Bras Reumatol Engl Ed. 2016;56(4):345-51. [DOI:10.1016/j.rbr.2015.09.010]
14. Nadimi H, Djazayery A, Javanbakht M H, Dehpour A, Ghaedi E, Derakhshanian H, et al. The Effect of Vitamin D Supplementation on Serum and Muscle Irisin Levels, and FNDC5 Expression in Diabetic Rats. Rep. of Bio. & Mol. Bio. 2019;8(3):236-243.
15. Bischoff-Ferrari HA, Dawson-Hughes B, Orav EJ, Staehelin HB, Meyer OW, Theiler R, et al. Monthly high-dose vitamin D treatment for the prevention of functional decline: a randomized clinical trial. JAMA Intern Med. 2016;176(2):175-83. [DOI:10.1001/jamainternmed.2015.7148] [PMID]
16. Roomi AB, AL-Salih RM, Ali SA. The Effect Insulin Therapy and Metformin on Osteoporosis in Diabetic Post-Menopausal Iraqi Women. Indian Journal of Public Health Research & Development. 2019;10(4):1544. [DOI:10.5958/0976-5506.2019.00935.5]
17. Morris HA, Eastell R, Jorgensen NR, Cavalier E, Vasikaran S, Chubb SA, et al. Clinical usefulness of bone turnover marker concentrations in osteoporosis. Clin Chim Acta. 2017;467:34-41. [DOI:10.1016/j.cca.2016.06.036] [PMID]
18. Piri F, Khosravi A, Moayeri A, Moradipour A, Derakhshan S. The effects of dietary supplements of calcium, vitamin D and estrogen hormone on serum levels of OPG and RANKL cytokines and their relationship with increased bone density in rats. J Clin Diagn Res. 2016;10(9):AF01-AF04. [DOI:10.7860/JCDR/2016/18648.8433] [PMID] [PMCID]
19. Rowland I, Gibson G, Heinken A, Scott K, Swann J, Thiele I, et al. Gut microbiota functions: metabolism of nutrients and other food components. Eur J Nutr. 2018;57(1):1-24. [DOI:10.1007/s00394-017-1445-8] [PMID] [PMCID]
20. Deng J, Feng Z, Li Y, Pan T, Li Q, Zhao C. Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis. Medicine (Baltimore). 2018;97(47):e13341. [DOI:10.1097/MD.0000000000013341] [PMID] [PMCID]
21. Chawla H, Saha S, Kandasamy D, Sharma R, Sreenivas V, Goswami R. Vertebral fractures and bone mineral density in patients with idiopathic hypoparathyroidism on long-term follow-up. J Clin Endocrinol Metab. 2017;102(1):251-258.
22. El Wakf AM, Hassan HA, Gharib NS. Osteoprotective effect of soybean and sesame oils in ovariectomized rats via estrogen-like mechanism. Cytotechnology. 2014;66(2):335-43. [DOI:10.1007/s10616-013-9580-4] [PMID] [PMCID]
23. Kharode YP, Sharp MC, Bodine PV. Utility of the ovariectomized rat as a model for human osteoporosis in drug discovery. Methods Mol Biol. 2008;455:111-24. [DOI:10.1007/978-1-59745-104-8_8] [PMID]
24. Manafi Rasi A, ., Amuzadeh Omrani F, Kazemian GH, Ebrahiminia MR, Khani S. Study of Calcaneus Bone Densitometry in Post-Menopausal Women. Asian J. Med. Pharm. Res. 2014;4(1):33-4.
25. Kanis JA, Cooper C, Rizzoli R, Reginster JY. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30(1):3-44. [DOI:10.1007/s00198-018-4704-5] [PMID] [PMCID]
26. Colaianni G, Grano M. Role of Irisin on the bone-muscle functional unit. Bonekey Rep. 2015;4:765. [DOI:10.1038/bonekey.2015.134] [PMID] [PMCID]
27. Nazirov FG, Khashimov ShKh, Makhmudov UM, Khaybullina ZR, Tuychiev OD. Effectiveness of stage by stage bariatric interventions for regression of comorbidity at obese class III patients. Journal of Life Science and Biomedicine. 2019;9(4):89-95.
28. Zhang J, Valverde P, Zhu X, Murray D, Wu Y, Yu L, et al. Exercise-induced irisin in bone and systemic irisin administration reveal new regulatory mechanisms of bone metabolism. Bone research. 2017;5(1):1-4. [DOI:10.1038/boneres.2016.56] [PMID] [PMCID]
29. Palermo A, Strollo R, Maddaloni E, Tuccinardi D, D'Onofrio L, Briganti SI, et al. Irisin is associated with osteoporotic fractures independently of bone mineral density, body composition or daily physical activity. Clin Endocrinol (Oxf). 2015;82(4):615-9. [DOI:10.1111/cen.12672] [PMID]
30. Zhang Y, Li R, Meng Y, Li S, Donelan W, Zhao Y, et al. Irisin stimulates browning of white adipocytes through mitogen-activated protein kinase p38 MAP kinase and ERK MAP kinase signaling. Diabetes. 2014;63(2):514-25. [DOI:10.2337/db13-1106] [PMID]
31. Dun SL, Lyu RM, Chen YH, Chang JK, Luo JJ, Dun NJ. Irisin-immunoreactivity in neural and non-neural cells of the rodent. Neuroscience. 2013;240:155-62. [DOI:10.1016/j.neuroscience.2013.02.050] [PMID] [PMCID]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2015 All Rights Reserved | Reports of Biochemistry and Molecular Biology

Designed & Developed by : Yektaweb